Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: Endothelial dysfunction, as a common underlying theme

Antioxidants and Redox Signaling

Volumn 7, Issue 11-12, 2005, Pages 1568-1580

  Pacher, Pál ^a   Szabó, Csaba ^b,c  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADVANCED GLYCATION END PRODUCT; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEXOSAMINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; POLYOL; PROTEIN KINASE C;

ADENOSINE DIPHOSPHATE RIBOSYLATION; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; ENZYME ACTIVATION; ENZYME INHIBITION; GLYCOLYSIS; HUMAN; HYPERGLYCEMIA; MICROVASCULATURE; NITROSATION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; DIABETES COMPLICATIONS; ENDOTHELIAL CELLS; ENZYME ACTIVATION; HUMANS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 28844462418     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2005.7.1568     Document Type: Review

References (120)

1. Affar EB, Shah RG, Dallaire AK, Castonguay V, and Shah GM. Role of poly(ADP-ribose) polymerase in rapid intracellular acidification induced by alkylating DNA damage. Proc Natl Acad Sci U S A 99: 245-250, 2002.
2. Anderson D, Yu TW, Wright J, and Ioannides C. An examination of DNA strand breakage in the comet assay and antioxidant capacity in diabetic patients. Mutat Res 398: 151-161, 1998.
3. Andreoli SP. Mechanisms of endothelial cell ATP depletion after oxidant injury. Pediatr Res 25: 97-101, 1989.
4. Astley S, Langrish-Smith A, Southon S, and Sampson M. Vitamin E supplementation and oxidative damage to DNA and plasma LDL in type 1 diabetes. Diabetes Care 22: 1626-1631, 1999.
5. Beckman JA. Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res 90: 107-111, 2002.
6. Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 26: 2433-2441, 2003.
7. Blundell G, Jones BG, Rose FA, and Tudball N. Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis 122: 163-172, 1996.
8. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001.
9. Bui BV, Armitage JA, Tolcos M, Cooper ME, and Vingrys AJ. ACE inhibition salvages the visual loss caused by diabetes. Diabetologia 46: 401-408, 2003.
10. Burkart V, Wang ZQ, Radons J, Heller B, Herceg Z, Stingl L, Wagner EF, and KoIb H. Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin. Nat Med 5: 314-319, 1999.
11. Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, Park JY, King GL, LoGerfo FW, Horton ES, and Veves A. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 48: 1856-1862, 1999.
12. Cai H and Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87: 840-844, 2000.
13. Cai H, Griendling KK, and Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 24: 471-478, 2003.
14. Calles-Escandon J, and Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 22: 36-52, 2001.
15. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 26: 1589-1596, 2003.
16. Ceriello A, Piconi L, Quagliaro L, Ros RD, Marini C, Giugliano D, et al Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose) polymerase. FASEB J 17: A260, 2003.
17. Cheng C and Zochodne DW. Sensory neurons with activated caspase-3 survive long-term experimental diabetes. Diabetes 52: 2363-2371, 2003.
18. 2 injury. J Neurochem 82: 19-29, 2002.
19. Cosentino F and Luscher TF. Endothelial dysfunction in diabetes mellitius. J Cardiavasc Pharmacol 32: S54-S61, 1998.
20. Csiszar A, Pacher P, Kaley G, and Ungvari Z. Role of oxidative and nitrosative stress, longevity genes and poly(ADP-ribose) polymerase in cardiovascular dysfunction associated with aging. Curr Vasc Pharmacol 3: 285-291, 2005.
21. Cuzzocrea S, Zingarelli B, Costantino G, Szabó A, Salzman AL, Caputi AP, and Szabó C. Beneficial effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase in a rat model of splanchnic artery occlusion and reperfusion. Br J Pharmacol 121: 1065-1074, 1997.
22. Cuzzocrea S, Zingarelli B, and Caputi AP. Role of peroxynitrite and poly (ADP-ribosyl) synthetase activation in cardiovascular derangement induced by zymosan in the rat. Life Sci 63: 923-933, 1998.
23. Davidovic L, Vodenicharov M, and Affar EB, Poirier GG. Importance of poly(ADP-ribose) glycohydrolase in the control of poly(ADP-ribose) metabolism. Exp Cell Res 268: 7-13, 2001.
24. De Murcia G and Shall S (Eds). From DNA Damage and Stress Signaling to Cell Death; Poly ADP-Ribosylation Reactions. Oxford: Oxford University Press, 2000.
25. De Murcia G, Schreiber V, Molinete M, Saulier B, Poch O, Massen M, Niedergang C, and Menissier de Murcia J. Structure and function of poly(ADP-ribose) polymerase. Mol Cell Biochem 138: 15-24, 1994.
26. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, and Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol 130: 963-974, 2000.
27. Dincer Y, Akcay T, Ilkova H, Alademir Z, and Ozbay G, DNA damage and antioxidant defense in peripheral leukocytes of patients with type I diabetes mellitus. Mutat Res 527: 49-55, 2003.
28. Du X, Matsumura T, Szabó C, Edelstein D, and Brownlee M. Hyperglycemia-induced superoxide activates PKC, the hexosamine pathway, AGE formation, and NF-κB via poly(ADP-ribose) polymerase inhibition of GAPDH. Diabetes 51(Suppl 2): A175, 2002.
29. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, and Brownlee M. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112: 1049-1057, 2003.
30. Ehrlich W, Huser H, and Kroger H. Inhibition of the induction of collagenase by interleukin-1 beta in cultured rabbit synovial fibroblasts after treatment with the poly(ADP-ribose)-polymerase inhibitor 3-aminobenzamide. Rheumatol Int 15: 171-172, 1995.
31. Eliasson MJ, Sampei K, Mandir AS, Hurn PD, Traystman RJ, Bao J, Pieper A, Wang ZQ, Dawson TM, Snyder SH, and Dawson VL. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat Med 3: 1089-1095, 1997.
32. Fukuda Y, Teragawa H, Matsuda K, Yamagata T, Matsuura H, and Chayama K. Tetrahydrobiopterin restores endothelial function of coronary arteries in patients with hypercholesterolaemia. Heart 87: 264-269, 2002.
33. Garcia Soriano F, Virág L, Jagtap P, Szabó É, Mabley JG, Liaudet L, Marton A, Hoyt DG, Murthy KG, Salzman AL, Southan GJ, and Szabo C. Diabetic endothelial dysfunction: the role of poly (ADP-ribose) polymerase activation. Nat Med 7: 108-113, 2001.
34. Giugliano D, Ceriello A, and Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 19: 257-267, 1996.
35. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, and Channon KM. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 86: E85-E90, 2000.
36. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, and Channon KM. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105: 1656-1662, 2002.
37. Herceg Z and Wang ZQ. Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat Res 477: 97-110, 2001.
38. Hiromatsu Y, Sato M, Yamada K, and Nonaka K. Nicotinamide and 3-aminobenzamide inhibit recombinant human interferon-gamma-induced HLA-DR antigen expression, but not HLA-A, B, C antigen expression, on cultured human thyroid cells. Clin Endocrinol 36: 91-95, 1992.
39. Hoyt DG and Lazo JS. Acute pneumocyte injury, poly(ADP-ribose) polymerase activity, and pyridine nucleotide levels after in vitro exposure of murine lung slices to cyclophosphamide. Biochem Pharmacol 48: 1757-1765, 1994.
40. + exchange. Circ Res 83: 644-651, 1998.
41. Hung TH, Skepper JN, Charnock-Jones DS, and Burton GJ. Hypoxia-reoxygenation: a potent inducer of apoptotic changes in the human placenta and possible etiological factor in preeclampsia. Circ Res 90: 1274-1281, 2002.
42. Jagtap P, Soriano FG, Virág L, Liaudet L, Mabley J, Szabó E, Haskó G, Marton A, Lorigados CB, Gallyas F Jr, Sumegi B, Hoyt DG, Baloglu E, VanDuzer J, Salzman AL, Southan GJ, and Szabó C. Novel phenanthridinone inhibitors of poly (adenosine 5′-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents. Crit Care Med 30: 1071-1082, 2002.
43. Junod AF, Jornot L, and Petersen H. Differential effects of hyperoxia and hydrogen peroxide on DNA damage, polyadenosine diphosphate-ribose polymerase activity, and nicotinamide adenine dinucleotide and adenosine triphosphate contents in cultured endothelial cells and fibrolasts. J Cell Physiol 140: 177-185, 1989.
44. Kirkland JB. Lipid peroxidation, protein thiol oxidation and DNA damage in hydrogen peroxide-induced injury to endothelial cells: role of activation of poly(ADP-ribose)polymerase. Biochim Biophys Acta 1092: 319-325, 1991.
45. Komjáti K, Jagtap P, Baloglu E, VanDuzer J, Salzman AL, and Szabó C. Poly(ADP-ribose) polymerase inhibition in stroke: establishment of the therapeutic window of intervention and delineation of its role in the pathogenesis of white matter damage. FASEB J 16: A599, 2002.
46. Kossenjans W, Rymaszewski Z, Barankiewicz J, Bobst A, and Ashraf M. Menadione-induced oxidative stress in bovine heart microvascular endothelial cells. Microcirculation 3: 39-47, 1996.
47. Landmesser U, Hornig B, and Drexler H. Endothelial dysfunction in hypercholesterolemia: mechanisms, pathophysiological importance, and therapeutic interventions. Semin Thromb Hemost 26: 529-537, 2000.
48. Lautier D, Lageux J, Thibodeau J, Ménard L, and Poirier GG. Molecular and biochemical features of poly (ADP-ribose) metabolism. Mol Cell Biochem 122: 171-193, 1993.
49. Le Rhun Y, Kirkland JB, and Shah GM. Cellular responses to DNA damage in the absence of poly(ADP-ribose) polymerase. Biochem Biophys Res Commun 245: 1-10, 1998.
50. Lewis EJ and Lewis JB. Treatment of diabetic nephropathy with angiotensin II receptor antagonist. Clin Exp Nephrol 1: 1-8, 2003.
51. Li F, Szabo C, Pacher P, Southan GJ, Abatan OI, Charniauskaya T, Stevens MJ, and Obrosova IG. Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy. Diabetology 47: 710-717, 2004.
52. Liaudet L, Soriano FG, Szabó E, Virág L, Mabley JG, Salzman AL, and Szabó C. Protection against hemorrhagic shock in mice genetically deficient in poly(ADP-ribose)polymerase. Proc Natl Acad Sci U S A 97: 10203-10208, 2000.
53. Lorenzi M, Montisano DF, Toledo S, and Wong HC. Increased single strand breaks in DNA of lymphocytes from diabetic subjects. J Clin Invest 79: 653-656, 1987.
54. Martinet W, Knaapen MW, De Meyer GR, Herman AG, and Kockx MM. Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Circulation 106: 927-932, 2002.
55. Menissier-de Murcia J, Niedergang C, Trucco C, Ricoul M, Dutrillaux B, Mark M, Oliver FJ, Masson M, Dierich A, LeMeur M, Waltzinger C, Chambon P, and de Murcia G. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A 94: 7303-7307, 1997.
56. Mihm MJ, Wattanapitayakul SK, Piao SF, Hoyt DG, and Bauer JA. Effects of angiotensin II on vascular endothelial cells: formation of receptor-mediated reactive nitrogen species. Biochem Pharmacol 65: 1189-1197, 2003.
57. Minchenko AG, Stevens MJ, White L, Abatan OI, Komjáti K, Pacher P, Szabo C, and Obrosova IG. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J 17: 1514-1516, 2003.
58. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, and Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404: 787-790, 2000.
59. Nitenberg A. Vascular endothelium: a target organ for diabetes mellitus. Ann Endocrinol (Paris) 63: S13-S17, 2002.
60. Obrosova IG. Update on the pathogenesis of diabetic neuropathy. Curr Diab Rep 3: 439-445, 2003.
61. Obrosova IG, Li F, Abatan OI, Komjáti K, Pacher P, Szabo C, and Stevens MJ. Poly(ADP-ribose) polymerase (PARP) activation in the development of diabetic neuropathy [Abstract]. FASEB J 17: A261, 2003.
62. Obrosova IG, Li F, Abatan OI, Forsell MA, Komjáti K, Pacher P, Szabo C, and Stevens MJ. Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 53: 711-720, 2004.
63. Obrosova IG, Mabley JG, Zsengeller Z, Charniauskaya T, Abatan OI, Groves JT, and Szabó C. Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst. FASEB J 19: 401-403, 2005.
64. Obrosova IG, Minchenko AG, Frank RN, Seigel GM, Zsengeller Z, Pacher P, Stevens MJ, and Szabo C. Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor (VEGF) overexpression. Int J Mol Med, 14: 55-64, 2004.
65. Obrosova IG, Pacher P, Szabó C, Zsengeller Z, Hirooka H, Stevens MJ, and Yorek MA. Aldose reductase inhibition counteracts oxidative/nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetic complications. Diabetes 54: 234-242, 2005.
66. Oei SL and Ziegler M. ATP for the DNA ligation step in base excision repair is generated from poly(ADP-ribose). J Biol Chem 275: 23234-23239, 2000.
67. Oikawa A, Tohda H, Kanai M, Miwa M, and Sugimura T. Inhibitors of poly(adenosine diphosphate ribose) polymerase induce sister chromatid exchanges. Biochem Biophys Res Commun 97: 1311-1316, 1980.
68. Oliver FJ, Menissier-de Murcia J, Nacci C, Decker P, Andriantsitohaina R, Muller S, de la Rubia G, Stoclet JC, and de Murcia G. Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J 18: 4446-4454, 1999.
69. Pacher P, Cziraki A, Mabley JG, Liaudet L, Papp L, and Szabo C. Role of poly(ADP-ribose) polymerase activation in endotoxin-induced cardiac collapse in rodents. Biochem Pharmacol 64: 1785-1791, 2002.
70. Pacher P, Liaudet L, Bai P, Virag L, Mabley J, Hasko G, and Szabo C. Activation of poly(ADP-ribose) polymerase contributes to the development of doxorubicin-induced heart failure. J Pharmacol Exp Ther 300: 862-687, 2002.
71. Pacher P, Liaudet L, Mabley J, Komjati K, and Szabo C. Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. J Am Coll Cardiol 40: 1006-1016, 2002.
72. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabó É, and Szabó C. The role of poly(ADP-ribose) polymerase in the development of myocardial and endothelial dysfunction in diabetes mellitus. Diabetes 51: 514-521, 2002.
73. Pacher P, Mabley JG, Soriano FG, Liaudet L, Komjati K, and Szabo C. Endothelial dysfunction in aging animals: the role of poly(ADP-ribose) polymerase activation. Br J Pharmacol 135: 1347-1350, 2002.
74. Pacher P, Mabley JG, Soriano FG, Liaudet L, and Szabo C. Activation of poly(ADP-ribose) polymerase contributes to the endothelial dysfunction associated with hypertension and aging. Int J Mol Med 9: 659-664, 2002.
75. Pacher P, Schulz R, Liaudet L, and Szabo C. Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci 26: 302-310, 2005.
76. Pacher P, Obrosova IG, Mabley JG, and Szabo C. Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies. Curr Med Chem 12: 267-275, 2005.
77. Pannirselvam M, Verma S, Anderson TJ, and Triggle CR. Cellular basis of endothelial dysfunction in small mesenteric arteries from spontaneously diabetic (db/db -/-) mice: role of decreased tetrahydrobiopterin bioavailability. Br J Pharmacol 136: 255-263, 2002.
78. Park KS, Kim JH, Kim MS, Kim JM, Kim SK, Choi JY,Chung MH, Han B, Kim SY, and Lee HK. Effects of insulin and antioxidant on plasma 8-hydroxyguanine and tissue 8-hydroxydeoxyguanosine in streptozotocin-induced diabetic rats. Diabetes 50: 2837-2841, 2001.
79. Park SD, Kim CG, and Kim MG. Inhibitors of poly(ADP-ribose) polymerase enhance DNA strand breaks, excision repair, and sister chromatid exchanges induced by alkylating agents. Environ Mutagen 5: 515-525, 1983.
80. Pieper AA, Brat DJ, Krug DK, Watkins CC, Gupta A, Blackshaw S, Verma A, Wang ZQ, and Snyder SH. Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. Proc Natl Acad Sci U S A 96: 3059-3064, 1999.
81. Poirier GG, de Murcia G, Jongstra-Bilen J, Niedergang C, and Mandel P. Poly(ADP-ribosyl)ation of polynucleosomes causes relaxation of chromatin structure. Proc Natl Acad Sci U S A 79: 3423-3427, 1982.
82. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, and Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 52: 2795-2804, 2003.
83. Reusch JE. Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose? J Clin Invest 112: 986-988, 2003.
84. Richardson D and Vinik A. Etiology and treatment of erectile failure in diabetes mellitus. Curr Diab Rep 2: 501-509, 2002.
85. Rudat V, Kupper JH, and Weber KJ. Trans-dominant inhibition of poly(ADP-ribosyl)ation leads to decreased recovery from ionizing radiation-induced cell killing. Int J Radiat Biol 73: 25-330, 1998.
86. Ruderman NB, Williamson JR, and Brownlee M. Glucose and diabetic vascular disease. FASEB J 6: 2905-2914, 1992.
87. Sardas S, Yilmaz M, Oztok U, Cakir N, and Karakaya AE. Assessment of DNA strand breakage by comet assay in diabetic patients and the role of antioxidant supplementation. Mutat Res 490: 123-129, 2001.
88. Satoh MS and Lindahl T. Role of poly(ADP-ribose) formation in DNA repair. Nature 356: 356-358, 1992.
89. Shimoda K, Murakami K, Enkhbaatar P, Traber LD, Cox RA, Hawkins HK, Schmatstieg FC, Kemjati K, Mabley JG, Szabo C, Salzman AL, and Traber DL. Effect of poly(ADP ribose) synthetase inhibition on burn and smoke inhalation injury in sheep. Am J Physiol Lung Cell Mol Physiol 285: L240-L249, 2003.
90. Simbulan-Rosenthal CM, Ly DH, Rosenthal DS, Konopka G, Luo R, Wang ZQ, Schultz PG, and Smulson ME. Misregulation of gene expression in primary fibroblasts lacking poly(ADP-ribose) polymerase. Proc Natl Acad Sci U S A 97: 11274-11279, 2000.
91. Soriano FG, Mabley JG, Pacher P, Liaudet L, and Szabó C. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ Res 89: 684-691, 2001.
92. Soriano FG, Virag L, and Szabo C. Diabetic endothelial dysfunction: role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation. J Mol Med 79: 437-448, 2001.
93. Soriano FG, Liaudet L, Szabo E, Virag L, Mabley JG, Pacher P, and Szabo C. Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1-deficient mice. Shock 17: 286-292, 2002.
94. Southan GJ and Szabo C. Poly(ADP-ribose) polymerase inhibitors. Curr Med Chem 10: 321-340, 2003.
95. Szabó C. Cell Death: The role of PARP. Boca Raton, FL: CRC Press, 2000.
96. Szabó C and Dawson VL. Role of poly (ADP-ribose) synthetase activation in inflammation and reperfusion injury. Trends Pharmacol Sci 19: 287-298, 1998.
97. Szabó C, Zingarelli B, O'Connor M, and Salzman AL. DNA strand breakage, activation of poly-ADP ribosyl synthetase, and cellular energy depletion are involved in the cytotoxicity in macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci U S A 93: 1753-1758, 1996.
98. Szabo C, Cuzzocrea S, Zingarelli B, O'Connor M, and Salzman AL. Endothelial dysfunction in a rat model of endotoxic shock: importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite. J Clin Invest 100: 723-735, 1997.
99. Szabó C, Wong H, Bauer PI, Kirsten E, O'Connor M, Zingarelli B, et al. Regulation of components of the inflammatory response by 5-iodo-6-amino-1,2-benzopyrone, an inhibitor of poly (ADP-ribose) synthetase and pleiotropic modifier of cellular signal pathways. Int J Oncol 10: 1093-1104, 1997.
100. Szabó C, Virág L, Cuzzocrea S, Scott GS, Hake P, O'Connor MP, Zingarelli B, Salzman A, and Kun E. Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly (ADP-ribose) synthetase. Proc Natl Acad Sci U S A 95: 3867-3872, 1998.
101. Szabo C, Mabley JG, Moeller SM, Shimanovich R, Pacher P, Virag L, Soriano FG, Van Duzer JH, Williams W, Salzman AL, and Groves JT. Pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med 8: 571-580, 2002.
102. Szabó C, Zanchi A, Komjati K, Pacher P, Krolewski AS, Quist WC, LoGerfo FW, Horton ES, and Veves A. Poly(ADP-ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation 106: 2680-2686, 2002.
103. Szabó C, Pachaer P, Komjati K, Mabley JG, Benko R, and Killai M. Poly(ADP-ribose) polymerase (PARP) activation is an early event in angiotensin-induced cardiovascular disorders [Abstract]. FASEB J 17: A803, 2003.
104. Szabó C, Pacher P, Zsengeller Z, Vaslin A, Komjati K, Benko R, Chen M, Mabley JG, and Kollai M. Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation. Mol Med 10: 28-35, 2004.
105. Szabó E, Kern TS, Virag L, Mabley J, and Szabó C. Evidence for poly(ADP-ribose) polymerase activation in the diabetic retina. FASEB J 15: A942, 2001.
106. Szabo G, Bahrle S, Stumpf N, Sonnenberg K, Szabó EE, Pacher P, Csont T, Schulz R, Dengler TJ, Liaudet L, Jagtap PG, Southan GJ, Vahl CF, Hagl S, and Szabo C. Poly(ADP-ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. Circ Res 90: 100-106, 2002.
107. Thiemermann C, Bowes J, Myint FP, and Vane JR. Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc Natl Acad Sci U S A 94: 679-683, 1997.
108. Thies RL and Autor AP. Reactive oxygen injury to cultured pulmonary artery endothelial cells: mediation by poly(ADP-ribose) polymerase activation causing NAD depletion and altered energy balance. Arch Biochem Biophys 286: 353-363, 1991.
109. Ullrich O, Ciftci O, and Hass R. Proteasome activation by poly-ADP-ribose-polymerase in human myelomonocytic cells after oxidative stress. Free Radic Biol Med 29: 995-1004, 2000.
110. Ungvari Z, Gupte SA, Recchia FA, Batkai S, and Pacher P. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol 3: 221-229, 2005.
111. Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H, Tordo P, and Pritchard KA Jr. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A 95: 9220-9225, 1998.
112. Verrotti A, Trotta D, Salladini C, Laura M, and Chiarelli F. Preventing microvascular diabetic complications in children and adolescents: looking beyond glycaemic control. Expert Opin Pharmacother 4: 525-532, 2003.
113. Vinik AI and Vinik E. Prevention of the complications of diabetes. Am J Manag Care 9(3 Suppl): S63-S80, 2003.
114. Virag L and Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54: 375-429, 2002.
115. Wahlberg G, Carlson LA, Wasserman J, and Ljungqvist A. Protective effect of nicotinamide against nephropathy in diabetic rats. Diabetes Res 2: 307-312, 1985.
116. Wattanapitayakul SK, Weinstein DM, Holycross BJ, and Bauer JA. Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders. FASEB J 14: 271-278, 2000.
117. Werner-Felmayer G, Golderer G, and Werner ER. Tetrahydrobiopterin biosynthesis, utilization and pharmacological effects. Curr Drug Metab 3: 159-173, 2002.
118. Zhang J (Ed). Therapeutic Implications of PARP Inhibition. Boca Raton, FL: CRC Press, 2002.
119. Zheng L, Szabo C, and Kern TS. Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear faction-kappaB. Diabetes 53: 2960-2967, 2004.
120. Zingarelli B, Salzman AL, and Szabó C. Genetic disruption of poly (ADP ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia-reperfusion injury. Circ Res 83: 85-94, 1998.